# Substack Bundle — Sinclair Says Age Reversal Is Already In Humans: What Is Actually Being Dosed, Why The Endpoint Is Vision Instead Of Aging, And What The FDA Would Need To Approve An Actual Geroprotector

## How to use
1. Open your Substack draft.
2. Drag audio_part1.mp3 into the post body — goes ABOVE the paywall divider.
   Substack converts it to a podcast player block (free listeners get this).
3. Add the paywall divider (---) below the Part I audio block.
4. Drag audio_part2.mp3 BELOW the paywall divider (paid subscribers only).
5. If video.mp4 is included, drag it above everything as the header embed.
6. Paste the show notes below the audio blocks.
7. Schedule publish — Substack auto-delivers to your paid podcast RSS feed.

## Files in this ZIP
- (no audio available)
- video.mp4 — short-form clip (argil_xthread_9_16)

## Episode title
Is Age Reversal Really In Humans?

## Preview / hook (top of post, free side)
A viral podcast clip from a Harvard geneticist claimed that human age reversal technology is in people right now. Nearly a million engagements followed. This episode works through what is actually being tested, why the eye is the first target, and why the gap between the headline and the clinical reality is where the entire story lives.

## Above-paywall intro
The podcast episode and full written analysis below are for paid subscribers. The free version of this episode covers what the viral claim actually refers to and why the regulatory framing matters. The paid tier goes deeper into the commercial economics, the clock problem, the cancer question, and the signals worth tracking.

## Paywall transition line
The full analysis is for paid subscribers.

## Paid CTA (after paywall)
Subscribe to On Healthcare to access the full episode and written breakdown. Paid subscribers get the complete regulatory, commercial, and scientific picture, including what to watch over the next two years.

## Show notes
A clip from a conversation between a Harvard geneticist and a podcast host is circulating with the claim that human age reversal technology is already in people. The engagement numbers are large. The useful analysis is sparse.

This episode walks through what the claim most likely refers to: a gene therapy program using three epigenetic reprogramming factors, delivered to retinal ganglion cells, in patients with a sudden optic nerve condition that has no approved treatment. It is legally a vision trial. The endpoint is letters on a chart. The word rejuvenation does not appear in the regulatory submission.

The episode also covers why the eye is always the first target for this class of therapy, why epigenetic clocks are weaker regulatory instruments than the marketing suggests, and why the question about cancer and dedifferentiation is the one that almost never gets asked in the long podcast format where these claims do the most work.
